Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition-Reference-Cited by-同舟云学术

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

Published:2017-11 Issue:7679 Volume:551 Page:247-250
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Hangauer Matthew J.,Viswanathan Vasanthi S.,Ryan Matthew J.,Bole Dhruv,Eaton John K.,Matov Alexandre,Galeas Jacqueline,Dhruv Harshil D.,Berens Michael E.,Schreiber Stuart L.,McCormick Frank,McManus Michael T.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature24297.pdf

Reference23 articles.

1. Groenendijk, F. H. & Bernards, R. Drug resistance to targeted therapies: déjà vu all over again. Mol. Oncol. 8, 1067–1083 (2014)

2. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010)

3. Raha, D. et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. 74, 3579–3590 (2014)

4. Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016)

5. Oxnard, G. R. The cellular origins of drug resistance in cancer. Nat. Med. 22, 232–234 (2016)

Cited by 1149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications;Non-coding RNA Research;2024-12

2. Drug tolerance and persistence in bacteria, fungi and cancer cells: Role of non-genetic heterogeneity;Translational Oncology;2024-11

3. Design, synthesis, and biological evaluation of RSL3-based GPX4 degraders with hydrophobic tags;European Journal of Medicinal Chemistry;2024-11

4. Emerging Therapeutic Approaches Targeting Ferroptosis in Cancer: Focus on Immunotherapy and Nanotechnology;Current Pharmaceutical Biotechnology;2024-11

5. SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors;Redox Biology;2024-10